

Raj Sengupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7046622/publications.pdf>

Version: 2024-02-01

93
papers

1,318
citations

411340

20
h-index

425179

34
g-index

97
all docs

97
docs citations

97
times ranked

1616
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit. <i>Rheumatology</i> , 2022, 61, 734-742.	0.9	6
2	The Future of Axial Spondyloarthritis Rehabilitation: Lessons Learned From COVID-19. <i>Arthritis Care and Research</i> , 2022, 74, 44-49.	1.5	4
3	P270-Act on Axial SpA: a gold standard time to diagnosis. <i>Rheumatology</i> , 2022, 61, .	0.9	1
4	P261-Early and accurate diagnosis of patients with axial spondyloarthritis using machine learning: a predictive analysis from electronic health records in the United Kingdom. <i>Rheumatology</i> , 2022, 61, .	0.9	2
5	Correlates of physical activity in adults with spondyloarthritis and rheumatoid arthritis: a systematic review. <i>Rheumatology International</i> , 2022, 42, 1693-1713.	1.5	9
6	A novel IMU-based clinical assessment protocol for Axial Spondyloarthritis: a protocol validation study. <i>PeerJ</i> , 2021, 9, e10623.	0.9	11
7	COSMIN reviews: the need to consider measurement theory, modern measurement and a prospective rather than retrospective approach to evaluating patient-based measures. <i>Journal of Medical Economics</i> , 2021, 24, 860-861.	1.0	5
8	Setting and maintaining standards for patient-reported outcome measures: can we rely on the COSMIN checklists?. <i>Journal of Medical Economics</i> , 2021, 24, 502-511.	1.0	18
9	Determinants of Longitudinal Adherence in Smartphone-Based Self-Tracking for Chronic Health Conditions. , 2021, 5, 1-24.		13
10	P177-Management of patients with axSpA: an audit against the NICE diagnosis and management of adults with spondyloarthritis quality standard, QS170, and clinical practice guidelines. <i>Rheumatology</i> , 2021, 60, .	0.9	0
11	P007-Service evaluation of the nurse-led telephone advice line in the wake of COVID-19: a report of audit and staff satisfaction. <i>Rheumatology</i> , 2021, 60, .	0.9	0
12	P181-Long-term improvement in axial spondyloarthritis clinical outcomes following 2-weeks of intensive education and rehabilitation: results from the Bath residential rehabilitation programme. <i>Rheumatology</i> , 2021, 60, .	0.9	0
13	P097-Raised inflammatory markers with unclear cause; what do they tell us? An audit of patients presenting to rheumatology service at RNHRD, Bath. <i>Rheumatology</i> , 2021, 60, .	0.9	0
14	Delayed diagnosis in axial spondyloarthritis-”how can we do better?. <i>Rheumatology</i> , 2021, 60, 4951-4952.	0.9	5
15	Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa063.	0.3	1
16	Understanding flare in axial spondyloarthritis: novel insights from daily self-reported flare experience. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab082.	0.3	2
17	Improving Scoring Precision and Internal Construct Validity of the Bath Ankylosing Spondylitis Disease Activity Index Using Rasch Measurement Theory. <i>Journal of Rheumatology</i> , 2020, 47, 354-361.	1.0	4
18	BRITSpA at five. <i>Rheumatology</i> , 2020, 59, 699-701.	0.9	0

#	ARTICLE	IF	CITATIONS
19	P269â€fLongitudinal patterns of pain distribution in axSpA patients: a retrospective cohort study. <i>Rheumatology</i> , 2020, 59, .	0.9	0
20	P271â€fAn analysis of short-term repeat MRI scans of vertebral corner lesions in suspected early axSpA: defining the prevalence and evolution of clinically significant spinal lesions without concurrent SIJ changes on imaging. <i>Rheumatology</i> , 2020, 59, .	0.9	0
21	P274â€fAssociation of self-reported symptoms and behaviour in axSpA: initial analyses from the Project Nightingale study. <i>Rheumatology</i> , 2020, 59, .	0.9	1
22	P284â€fCertolizumab pegol-treated patients with non-radiographic axSpA demonstrate improvements in sleep quality and other patient reported outcomes. <i>Rheumatology</i> , 2020, 59, .	0.9	0
23	P285â€fUsing FITBITR for fitness monitoring in patients attending the AS residential course at RNHRD: it does make a difference!. <i>Rheumatology</i> , 2020, 59, .	0.9	0
24	P286â€fExamining the relationships between important other autonomy support, basic psychological need satisfaction and well-being in those with non-radiographic AxSpA. <i>Rheumatology</i> , 2020, 59, .	0.9	0
25	Axial spondyloarthritis 10 years on: still looking for the lost tribe. <i>Rheumatology</i> , 2020, 59, iv25-iv37.	0.9	29
26	P263â€fShould we advocate biologic dose-reduction in patients with AxSpA?. <i>Rheumatology</i> , 2020, 59, .	0.9	0
27	Corrigendum to: An analysis of short-term repeat MRI scans of vertebral corner lesions in suspected early axSpA: defining the prevalence and evolution of clinically significant spinal lesions without concurrent SIJ changes on imaging. <i>Rheumatology</i> , 2020, 59, 2654-2654.	0.9	0
28	Longitudinal profiling of the gut microbiome in patients with psoriatic arthritis and ankylosing spondylitis: a multicentre, prospective, observational study. <i>BMC Rheumatology</i> , 2020, 4, 60.	0.6	1
29	Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa015.	0.3	3
30	Physical therapy in axial spondyloarthritis: guidelines, evidence and clinical practice. <i>Current Opinion in Rheumatology</i> , 2020, 32, 365-370.	2.0	16
31	The Future of Axial Spondyloarthritis Treatment. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 357-365.	0.8	5
32	Practical Approaches to Bone Marrow Fat Fraction Quantification Across Magnetic Resonance Imaging Platforms. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 298-306.	1.9	15
33	Evaluating patient-reported fatigue and serum biomarkers in axial spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 3111-3113.	0.9	3
34	Back pain, ankylosing spondylitis and social media usage; a descriptive analysis of current activity. <i>Rheumatology International</i> , 2020, 40, 1493-1499.	1.5	7
35	Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath. <i>Clinical Rheumatology</i> , 2020, 39, 1501-1504.	1.0	15
36	Living with ankylosing spondylitis: an open response survey exploring physical activity experiences. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz016.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Awareness of axial spondyloarthritis among chiropractors and osteopaths: findings from a UK Web-based survey. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz034.	0.3	12
38	O36â€fExploring NICE criteria for continuing biologic therapies in axial spondyloarthritis: what is a suboptimal response?. <i>Rheumatology</i> , 2019, 58, .	0.9	0
39	246â€fSafety and effectiveness of certolizumab pegol in axial spodyloarthritis in a real-world setting: a UK sub-analysis from a European non-interventional study. <i>Rheumatology</i> , 2019, 58, .	0.9	0
40	269â€fIn axial spondyloarthritis, magnitude of improved disease activity after six months of biologic disease-modifying treatment may be more relevant to short-term functional outcome than achieving an inactive disease state. <i>Rheumatology</i> , 2019, 58, .	0.9	0
41	Measurement of patient-reported outcomes. 1: The search for the Holy Grail. <i>Journal of Medical Economics</i> , 2019, 22, 516-522.	1.0	31
42	AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). <i>BMC Rheumatology</i> , 2019, 3, 19.	0.6	10
43	Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz012.	0.3	4
44	Use of Complementary and Alternative Medicine in Axial Spondyloarthritis: A Qualitative Exploration of Self-Management. <i>Journal of Clinical Medicine</i> , 2019, 8, 699.	1.0	3
45	Recommendations for acquisition and interpretation of MRI of the spine and sacroiliac joints in the diagnosis of axial spondyloarthritis in the UK. <i>Rheumatology</i> , 2019, 58, 1831-1838.	0.9	35
46	O33â€fRecommendations for acquisition and considerations for interpretation of MRI of the spine and sacroiliac joints in the investigation of axial spondyloarthritis in the UK. <i>Rheumatology</i> , 2019, 58, .	0.9	0
47	Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 281.	1.0	3
48	Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy. <i>Rheumatology and Therapy</i> , 2019, 6, 165-177.	1.1	32
49	(Un)Spoken realities of living with axial spondyloarthritis: a qualitative study focused on couple experiences. <i>BMJ Open</i> , 2019, 9, e025261.	0.8	3
50	FRIO414â€f...SECUKINUMAB PROVIDES RAPID AND SIGNIFICANT IMPROVEMENT IN THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS: PRIMARY (16-WEEK) RESULTS FROM A PHASE 3 CHINA-CENTRIC STUDY, MEASURE 5. , 2019, , .		3
51	THU0377â€f...THE CARDIOVASCULAR ASSOCIATIONS WITH ENTHESITIS AND DACTYLITIS IN PATIENTS WITH SPONDYLOARTHRITIS: RESULTS FROM THE ASAS-COMOSPA STUDY. , 2019, , .		0
52	THU0408â€f...ACHIEVING DISEASE REMISSION IN AXIAL SPONDYLOARTHRITIS: A TWO-CENTRE RETROSPECTIVE ANALYSIS OF RELEVANT BASELINE PATIENT CHARACTERISTICS. , 2019, , .		0
53	Three Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 258-270.	2.9	237
54	Measurement of patient-reported outcomes. 2: Are current measures failing us?. <i>Journal of Medical Economics</i> , 2019, 22, 523-530.	1.0	33

#	ARTICLE	IF	CITATIONS
55	Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2019, 46, 701-709.	1.0	21
56	Exploring the Future Role of Self-Tracking Data in the Rheumatology Clinic. <i>Studies in Health Technology and Informatics</i> , 2019, 259, 33-38.	0.2	0
57	Biologics for treating axial spondyloarthritis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 641-652.	1.4	20
58	Sleep in ankylosing spondylitis and non-radiographic axial spondyloarthritis: associations with disease activity, gender and mood. <i>Clinical Rheumatology</i> , 2018, 37, 1045-1052.	1.0	15
59	163â€fA multi-centre retrospective study to describe the real world effectiveness of golimumab for treating ankylosing spondylitis (AS) in UK clinical practice. <i>Rheumatology</i> , 2018, 57, .	0.9	0
60	Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritisâ€™findings from a United Kingdom cohort. <i>Rheumatology</i> , 2018, 57, 619-624.	0.9	28
61	A truly complementary approach: A qualitative exploration of complementary and alternative medicine practitioners' views of treating ankylosing spondylitis. <i>Musculoskeletal Care</i> , 2018, 16, 96-102.	0.6	7
62	The clinical utility of human leucocyte antigen B27 in axial spondyloarthritis. <i>Rheumatology</i> , 2018, 57, 959-968.	0.9	16
63	Short-term Repeat Magnetic Resonance Imaging Scans in Suspected Early Axial Spondyloarthritis Are Clinically Relevant Only in HLA-B27â€™positive Male Subjects. <i>Journal of Rheumatology</i> , 2018, 45, 202-205.	1.0	18
64	001â€™Do patients with axial spondyloarthritis who meet research criteria for fibromyalgia benefit from biologic therapy?. <i>Rheumatology</i> , 2018, 57, .	0.9	0
65	Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritisâ€™findings from a United Kingdom cohort: reply. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky037.	0.3	0
66	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. <i>Rheumatology</i> , 2018, 57, 1982-1990.	0.9	26
67	Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?. <i>Rheumatology International</i> , 2017, 37, 327-336.	1.5	9
68	Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 701-707.	0.5	152
69	Prevalence and factors associated with disturbed sleep in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review. <i>Rheumatology International</i> , 2017, 37, 257-271.	1.5	42
70	Monitoring patients with ankylosing spondylitis on anti-TNF monotherapy: too much too often?. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 330-331.	0.6	1
71	BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	0.9	41
72	Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. <i>Arthritis Research and Therapy</i> , 2017, 19, 210.	1.6	40

#	ARTICLE	IF	CITATIONS
73	115.â€fSURVIVAL ANALYSIS AND REASONS FOR DISCONTINUING OR SWITCHING TUMOUR NECROSIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHRITIS: FINDINGS FROM A REAL-LIFE UK COHORT. <i>Rheumatology</i> , 2017, 56, .	0.9	0
74	SPONDYLARTHROPATHIES (INCLUDING PSORIATIC ARTHRITIS)099.â€fSMOKING EXPOSURE IS ASSOCIATED WITH INCREASED DISEASE SEVERITY IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR ANKYLOSING SPONDYLITIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
75	E70.â€fA QUALITATIVE EXPLORATION OF THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE THERAPIES IN AXIAL SPONDYLOARTHRITIS: INFORMING A REDUCTION IN THE DELAY TO DIAGNOSIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
76	I45.â€fANKYLOSING SPONDYLITIS: ANTIâ€TUMOUR NECROSIS FACTOR AND BEYOND. <i>Rheumatology</i> , 2017, 56,0.9	0.9	0
77	Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 571-578.	0.4	23
78	Comment on: delay to diagnosis in axial spondyloarthritis: are we improving in the UK?: Reply. <i>Rheumatology</i> , 2016, 55, 1707-1708.	0.9	0
79	Clinical Outcomes and Progression to Orthopedic Surgery in Juvenileâ€Versus Adultâ€Onset Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2015, 67, 651-657.	1.5	19
80	Delay to diagnosis in axial spondyloarthritis: are we improving in the UK?: Fig. 1. <i>Rheumatology</i> , 2015, 54, kev288.	0.9	57
81	Serum Soluble Bone Turnover Biomarkers in Psoriatic Arthritis and Psoriatic Spondyloarthropathy. <i>Journal of Rheumatology</i> , 2015, 42, 21-30.	1.0	51
82	I80.â€fWhy Measure Disease Activity and What Should we Aim to Achieve?. <i>Rheumatology</i> , 2014, 53, i17-i17.	0.9	0
83	154.â€fDevelopment of Local Guidelines for the Management of Patients on Biologic Therapy Following Exposure to or Infection with Varicella Zoster Virus. <i>Rheumatology</i> , 2014, 53, i117-i118.	0.9	0
84	84.â€fEfficacy of As-Needed Rituximab in Patients with Rheumatoid Arthritis: A Single Centre Review of Routine Clinical Practice. <i>Rheumatology</i> , 2014, 53, i87-i87.	0.9	0
85	Feasibility, Reliability, and Sensitivity to Change of Four Radiographic Scoring Methods in Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 311-317.	1.5	21
86	223.â€fDelay to Diagnosis in Axial Spondyloarthritis: Are we Improving?. <i>Rheumatology</i> , 2014, 53, i143-i143.	0.9	1
87	"Talking AS". <i>International Journal of Integrated Care</i> , 2014, 14, .	0.1	0
88	Juvenile Versus Adult-onset Ankylosing Spondylitis â€ Clinical, Radiographic, and Social Outcomes. A Systematic Review. <i>Journal of Rheumatology</i> , 2013, 40, 1797-1805.	1.0	34
89	Expanding the spectrum of inflammatory spinal disease: AS it was, as it is now. <i>Rheumatology</i> , 2013, 52, 2103-2105.	0.9	6
90	Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. <i>Rheumatology</i> , 2013, 52, 261-266.	0.9	36

#	ARTICLE	IF	CITATIONS
91	Challenges in the management and research of juvenile-onset ankylosing spondylitis. International Journal of Clinical Rheumatology, 2013, 8, 615-617.	0.3	0
92	The assessment of ankylosing spondylitis in clinical practice. Nature Clinical Practice Rheumatology, 2007, 3, 496-503.	3.2	45
93	Performance of the Spade Tool to Identify Spondyloarthritis in Patients Referred to a Specialist. Rheumatology, 0, , .	0.9	0